Tag: phenox

Final results from the PROST randomised controlled trial (RCT) have been published in JAMA Neurology and—according to the study’s leading investigators—provide evidence that thrombectomy...

Phenox, a Wallaby Medical company, has today announced the presentation of the primary results of the PROST (Preset for occlusive stroke treatment) randomised clinical...

Phenox, a Wallaby Medical company, has announced the US Food and Drug Administration (FDA) 510(k) clearance of its Preset thrombectomy device for the treatment...

 Based on his leading experience with the hydrophilic polymer coating (HPC)-coated pEGASUS stent (phenox) at his centre, and positive, early observations of this easy-to-use...

Wallaby/phenox has officially announced the successful global launch of its novel Pegasus hydrophilic polymer coating (HPC) stent, having first unveiled the device at the 2022...

This advertorial is sponsored by phenox. Following the publication of a study assessing the use of Hydrophilic Polymer Coating (HPC) technology with the p64 MW...

Wallaby Medical today announced that it has acquired phenox GmbH—including phenox's femtos GmbH—for a total consideration of approximately €500 million including milestone payments. The acquisition is...

The Diversion-p64 study—the largest prospective study using the p64 flow modulation device (phenox) to date—has demonstrated that the device has a high level of...

Phenox has added to its extensive technology portfolio with the introduction of the pRESET 6-50 mechanical thrombectomy device for the treatment of acute large...

This year’s Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT 2021; 8–10 September, Nice, France and virtual) saw details of the...

Following its acceptance into Frontiers in Neurology, Phenox has announced the results of a paper exploring the benefit of choosing a longer stentriever for...

phenox GmbH has announced the opening of a permanent UK office in the south of Birmingham, UK. The company states in a press release...

phenox has announced the full European launch of the pRESET 5–40 and pRESET LUX 4–20 thrombectomy devices after receiving CE mark approval last year....

  phenox has announced the European launch of the new p64 MW Flow modulation device, intended for the treatment of intracranial aneurysms. The device received...

Phenox announces that it has signed an exclusive distribution agreement with Wallaby Medical for commercialisation of the Avenir Detachable Coil System in the US...

Investigators using the p64 Flow Modulation Device (Phenox) for the treatment of unruptured intracranial aneurysms at six centres have revealed that mid- and long-term...

The treatment of mechanical thrombectomy represents a highly effective therapy in patients with acute ischaemic stroke. This was recently proven by four randomised controlled...

The phenox pREset and pREset LITE thrombectomy devices have been included in the study portfolio of the SITS Open clinical trial. Two other devices...

In the first study to be published reporting on endovascular aneurysm treatment with the p64 flow modulation device (Phenox), Francesco Briganti and colleagues have found that the device provides a safe procedure with no technical complications.

Phenox GmbH has announced the start of the pToWin study after enrolling the first patient on 2 September, 2015. The prospective, multicentre, single-arm study...

The pCONus implant for treatment of complex, wide neck intracranial bifurcation aneurysms has been granted the CE mark for commericalisation in Europe.

The p64 Flow Modulation Device is an intraluminal flow diverter for treatment of complex intracranial aneurysms and dissections.